Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. September 2020 10:20 ET | Quelle: Genmab A/S

Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020

Media Release COPENHAGEN, Denmark and BOTHELL, Wash., 21 September 2020 Data featured in late-breaking proffered paper oral presentation Biologics license application submission planned to support...
10. September 2020 08:06 ET | Quelle: Genmab A/S

Genmab Announces that Janssen has Submitted a Supplemental Biologics License Application to U.S. FDA for use of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in Patients with Light-chain (AL) Amyloidosis

Media Release Copenhagen, Denmark, September 10, 2020 ·Janssen submitted an sBLA to U.S. FDA for DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in combination with bortezomib,...
09. September 2020 08:47 ET | Quelle: Genmab A/S

Genmab to Present at Morgan Stanley 18th Annual Global Healthcare Conference

Media Release Copenhagen, Denmark, 09 September, 2020 Genmab A/S (Nasdaq:GMAB) announced today that its CEO, Jan van de Winkel, Ph.D. and CFO Anthony Pagano, will participate in a virtual fireside...
26. August 2020 18:05 ET | Quelle: Genmab A/S

Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020

Media Release Copenhagen, Denmark, Aug 27, 2020 InnovaTV 204 study evaluated tisotumab vedotin in recurrent or metastatic cervical cancer Data from the study selected as a late-breaking abstract at...
20. August 2020 16:40 ET | Quelle: Genmab A/S

Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX® (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Company Announcement DARZALEX® (daratumumab) approved by U.S. FDA in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who...
20. August 2020 16:06 ET | Quelle: Genmab A/S

Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.

Company Announcement Novartis intends to transition availability of Arzerra® (ofatumumab) to an oncology access program for chronic lymphocytic leukemia patients in the U.S. Genmab receives USD 30...
20. August 2020 13:33 ET | Quelle: Genmab A/S

U.S. FDA Approves Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis

Company Announcement Kesimpta® (ofatumumab) approved by U.S. FDA for the treatment of relapsing forms of multiple sclerosis in adultsFirst B-cell therapy that can be self-administered using...
18. August 2020 15:40 ET | Quelle: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement Copenhagen, Denmark; August 18, 2020 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 62,716 shares as a consequence of the exercise of employee warrants. The...
12. August 2020 11:23 ET | Quelle: Genmab A/S

Genmab Announces Financial Results for the First Half of 2020

August 12, 2020; Copenhagen, Denmark; Interim Report for the First Half of 2020 Highlights ·Genmab and AbbVie enter into broad oncology collaboration; USD 750 million upfront payment with...
31. Juli 2020 15:38 ET | Quelle: Genmab A/S

Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Company Announcement Phase 3 APOLLO randomized study evaluating subcutaneous daratumumab in combination with pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in relapsed or...

Vorherige Seite

Nächste Seite